A Study to Estimate Health State Utilities Representing Preferences Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide
Latest Information Update: 12 Aug 2021
Price :
$35 *
At a glance
- Drugs Dulaglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Jul 2021 Results assessing utility differences between oral and injectable ROA, while highlighting the impact of treatment administration details on patient preference published in the Quality of Life Research
- 23 Jul 2020 New trial record
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.